Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–12 of 12 results
Advanced filters: Author: Gregg C. Fonarow Clear advanced filters

  • Monitoring for worsening congestion in patients with chronic heart failure has proven to be very challenging. The CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION) trial has now demonstrated that wireless monitoring of pulmonary artery pressures is safe and reduces rates of hospitalization.

    • Gregg C. Fonarow
    News & Views
    Nature Reviews Cardiology
    Volume: 8, P: 245-246

  • Nearly 25% of patients hospitalized for heart failure are readmitted within 30 days after discharge and have poor clinical outcome, in a period known as the 'vulnerable phase'. In this Review, Greene and colleagues highlight the considerations and outline a progressive management approach for reducing mortality and morbidity in patients with heart failure during this early postdischarge period.

    • Stephen J. Greene
    • Gregg C. Fonarow
    • Mihai Gheorghiade
    Reviews
    Nature Reviews Cardiology
    Volume: 12, P: 220-229

  • Heart failure (HF) is a global epidemic affecting >37.7 million individuals globally. HF is associated with increased morbidity and mortality, and confers a substantial burden on the health-care system. In this Review, Ziaeian and Fonarow summarize the latest epidemiological data on HF in both developed and developing countries, and provide an overview of associated risk factors and aetiologies contributing to the disease burden.

    • Boback Ziaeian
    • Gregg C. Fonarow
    Reviews
    Nature Reviews Cardiology
    Volume: 13, P: 368-378

  • The selection of end points for clinical trials of heart failure is challenging, with important implications for patients, the medical community, and regulatory agencies. The standards used in clinical research on patients with heart failure influence the effectiveness and value of future clinical trials, and the extent to which they can be translated into clinical practice.

    • Boback Ziaeian
    • Gregg C. Fonarow
    News & Views
    Nature Reviews Cardiology
    Volume: 10, P: 492-494

  • Heart failure and renal dysfunction frequently coexist. The term cardiorenal syndrome (CRS) is frequently used to describe this scenario, but the definition of CRS has been a matter of debate and has evolved over time. Here, the authors review the concept of CRS and its evolution and classification, and describe current and future targets for the clinical management of CRS. In addition, they propose a new classification system with seven distinct categories.

    • Parta Hatamizadeh
    • Gregg C. Fonarow
    • Kamyar Kalantar-Zadeh
    Reviews
    Nature Reviews Nephrology
    Volume: 9, P: 99-111

  • Heart failure (HF) is a clinical syndrome that carries substantial morbidity and mortality. The prevalence of HF is increasing and represents a large burden to the health-care system and society. The authors of this Review discuss the epidemiology of HF and the impact of HF on health services. The risk profile of HF is also examined, highlighting factors that contribute to HF and identifying those who are most at risk of developing this syndrome.

    • Anh L. Bui
    • Tamara B. Horwich
    • Gregg C. Fonarow
    Reviews
    Nature Reviews Cardiology
    Volume: 8, P: 30-41

  • Although cardiovascular disease is the most common cause of death among people with chronic renal dysfunction, conventional cardiovascular risk factors are paradoxically associated with improved survival in hemodialysis populations. Here, the authors analyze emerging data that support this 'reverse epidemiology'. Confirmation of this phenomenon might lead to the formulation of more effective management strategies, tailored to patient characteristics and disease stage.

    • Kamyar Kalantar-Zadeh
    • Csaba P Kovesdy
    • Gregg C Fonarow
    Reviews
    Nature Clinical Practice Nephrology
    Volume: 3, P: 493-506

  • In this Review, Khan and colleagues discuss the benefits and challenges of including pragmatism in the design, conduct and interpretation of randomized controlled trials (RCTs) for cardiovascular disease and highlight selected ongoing and completed cardiovascular RCTs that incorporate a pragmatic design.

    • Muhammad Shariq Usman
    • Harriette G. C. Van Spall
    • Muhammad Shahzeb Khan
    Reviews
    Nature Reviews Cardiology
    Volume: 19, P: 737-750